معرفی
Aline Delva serves as a Clinical Lecturer at KU Leuven's Faculty of Medicine, where she is affiliated with the Parkinson's Research Laboratory. Her academic activities integrate clinical neurology with advanced nuclear medicine techniques, focusing on diagnostic differentiation of neurodegenerative disorders through biomarker discovery and neuroimaging validation. She contributes to undergraduate medical education through specialized neurology skills courses and advanced neurobiology modules.
Dr. Delva's research centers on Parkinsonian syndromes, dementia with Lewy bodies, and Huntington's disease, with particular emphasis on cardiac noradrenergic imaging using [18F]-MFBG PET and [123I]-MIBG SPECT. Her work explores plasma biomarkers (pTau181, amyloid, astrocytic markers) for predicting dementia conversion in idiopathic REM sleep behavior disorder, investigates synaptic density changes in early neurodegeneration, and develops radioligands for mutant huntingtin imaging. She actively examines environmental risk factors like nicotine exposure in Parkinson's disease pathogenesis.
Analysis of her 2023-2025 publications reveals consistent methodological focus on comparative neuroimaging validation and biomarker discovery across multiple neurodegenerative conditions. Key thematic clusters include cardiac sympathetic imaging for differential diagnosis of Parkinson's disease versus multiple system atrophy, plasma biomarker trajectories in prodromal dementia, and Huntington's disease imaging biomarker standardization. Her collaborative work spans international consortia including the European Huntington's Disease Network.
No scientific awards are documented in the available information.
Dr. Delva holds co-promoter roles in two major research projects: a prospective comparison of cardiac [18F]-MFBG PET versus [123I]-MIBG SPECT for differential diagnosis of Parkinson's disease and related disorders (2023-2027), and investigation of [18F]-MFBG PET for early differentiation in Parkinson's disease and dementia with Lewy bodies (2023-2027). While formal student listings are absent, her laboratory mentorship likely extends to junior researchers through the Parkinson's Research Laboratory and clinical teams.
She operates within KU Leuven's Parkinson's Research Laboratory, collaborating with nuclear medicine specialists at University Hospitals Leuven and participating in the European Huntington's Disease Network Imaging Working Group. Her multidisciplinary team integrates neurologists, nuclear medicine physicians, and basic scientists to translate imaging findings into clinical diagnostic applications for neurodegenerative disorders.